MEDCATH CORPORATION 
By CHARLOTTE, N.C, Dec. 14, 2011 /PRNewswire/ -- MedCath Corporation (Nasdaq: MDTH), a healthcare provider focused on high acuity healthcare services, today announced operating results for its fourth fiscal quarter ended September 30, 2011.
Fourth Fiscal Quarter Highlights
-- Net revenue of $42.5 million, up 2.6% compared to the fourth quarter of
fiscal 2010.
-- Total admissions and adjusted admissions of 1,785 and 2,930, down 10.3%
and 10.2%, respectively, compared to the fourth quarter of fiscal 2010.
-- Loss from continuing operations of ($10.1) million and Adjusted EBITDA
of $(6.3) million.
-- Diluted loss per share from continuing operations of ($0.57) and
Adjusted EPS of ($0.33).
-- Total cash of $304.4 million, which includes cash held at entities
previously sold and cash used to fund a $139.4 million liquidating
dividend on October 13, 2011.
Adoption of Liquidating Accounting
On September 22, 2011, at a special meeting of stockholders, MedCath's stockholders approved the following:
-- The sale of all or substantially all of MedCath's remaining assets prior
to filing a certificate of dissolution, and
-- The complete liquidation of MedCath once the Board of Directors of
MedCath concludes that the implementation of a formal plan of
dissolution was in the best interest of MedCath and its stockholders.
Accordingly, MedCath adopted the liquidation basis of accounting as of September 22, 2011 since the liquidation and dissolution of MedCath was determined to be imminent. Please refer to MedCath's Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission December 14, 2011, for additional information regarding our adoption of the liquidation basis of accounting, our estimate of net asset value derived from our liquidation, risks relating to an investment in MedCath and risks relating to our liquidation and dissolution.
Financial results provided in this release are on a going concern basis for MedCath's operating activity through September 30, 2011, and include, among other items, the consolidated results of three hospitals: Bakersfield Heart Hospital, Louisiana Medical Center and Heart Hospital and Hualapai Mountain Medical Center. Louisiana Medical Center and Heart Hospital and Hualapai Mountain Medical Center were sold effective September 30, 2011. MedCath's financial results in this release also include MedCath's percentage of the net income of Harlingen Medical Center, which is accounted for pursuant to the equity method of accounting since MedCath did not own a majority of Harlingen Medical Center. MedCath sold its interest in Harlingen Medical Center on November 30, 2011.
Fourth Quarter of Fiscal 2011 Results Compared to Fourth Quarter of Fiscal 2010 Results
MedCath's reported net revenue increased 2.6% to $42.5 million in the fourth quarter of fiscal 2011 compared to $41.4 million in the fourth quarter of fiscal 2010. Net income was $30.8 million in the fourth quarter of fiscal 2011 compared to a net loss of $(21.7) million in the fourth quarter of fiscal 2010. MedCath's loss from continuing operations was $(10.1) million, or $(0.57) per diluted share, in the fourth quarter of fiscal 2011 compared to $(22.2) million, or $(1.33) per diluted share, in the fourth quarter of fiscal 2010.
MedCath's fourth quarter of fiscal 2011 financial results include the following items:
-- $7.0 million, or ($0.21) per diluted share, of professional fees and
other expenses incurred in connection with MedCath's strategic options
process announced on March 1, 2010; and
-- $1.0 million, or ($0.03) per diluted share, in share-based compensation
expense.
MedCath's fourth quarter of fiscal 2010 financial results include the following items:
-- $28.5 million, or ($0.87) per diluted share, in impairment expense;
-- $0.8 million, or ($0.02) per diluted share, in share-based compensation
expense; and
-- $2.6 million, or ($0.08) per diluted share, of professional fees and
other expenses incurred in connection with MedCath's strategic options
process announced on March 1, 2010.
Adjusted EBITDA was $(6.3) million in the fourth quarter of fiscal 2011 compared to $(0.5) million in the same period of the prior year. MedCath's Adjusted EPS for the fourth quarter of fiscal 2011 was $(0.33) compared with $(0.36) in the fourth quarter of fiscal 2010.
Operating Statistics
MedCath's financial results for the fourth fiscal quarter ended September 30, 2011, reflect a 10.3% decrease in total admissions and a 10.2% decrease in adjusted admissions compared to the fourth quarter of fiscal 2010. Volumes during the quarter were negatively impacted by the closing of Hualapai Mountain Medical Center, which began to wind down its operations on September 1, 2011. Hospital outpatient cases, including emergency department visits, totaled 9,995 in the fourth quarter of fiscal 2011, up 2.0% compared to the fourth quarter of fiscal 2010.
Total uncompensated care, which includes charity care plus bad debt expense, equaled 21.8% of hospital division net patient revenue before the deduction for charity care in the fourth quarter of fiscal 2011 compared to 16.2% in the fourth quarter of fiscal 2010.
Update on Strategic Options Process
On December 1, 2011, MedCath announced the completion of a transaction related to the sale of its equity interest in Harlingen Medical Center and HMC Realty, LLC, representing the twelfth transaction since MedCath announced its strategic options process in March 2010. MedCath anticipates that final net proceeds from this transaction, after payment of income tax due on the gain on sale, to be approximately $0.3 million. As a result, MedCath currently owns an interest in and operates only one hospital, located in Bakersfield, California.
Use of Non-GAAP Financial Measures
Included in this press release and the supplemental financial information furnished herewith are certain financial measures that are not calculated and presented in conformity with generally accepted accounting principles ("non-GAAP measures"), such as adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") and adjusted diluted earnings per share from continuing operations ("Adjusted EPS"). The supplemental financial information furnished herewith provides a quantitative reconciliation of Adjusted EBITDA and Adjusted EPS based on the following calculations as and for the periods identified below.
Adjusted EBITDA for the fourth fiscal quarter of 2011 represents MedCath's loss from continuing operations, net of taxes attributable to MedCath's common stockholders; income tax benefit, net income attributable to noncontrolling interests; equity in net earnings (losses) of unconsolidated affiliates; interest and other income; interest expense; (gain) loss on disposal of property, equipment and other assets; depreciation; share-based compensation expense, and professional fees associated with MedCath's exploration of strategic options. Adjusted EPS for the fourth fiscal quarter of fiscal 2011 represents MedCath's diluted loss per share from continuing operations adjusted for professional fees associated with MedCath's consideration of strategic options and share-based compensation expense.
Adjusted EBITDA for the fourth fiscal quarter of 2010 represents MedCath's loss from continuing operations, net of taxes, income tax benefit; net income attributable to noncontrolling interests; equity in earnings (losses) of unconsolidated affiliates; interest and other income; interest expense; (gain) loss on disposal of property, equipment and other assets; impairment of long-lived assets; depreciation; share-based compensation expense, and professional fees associated with MedCath's exploration of strategic options. Adjusted EPS for the fourth fiscal quarter of fiscal 2010 represents MedCath's diluted loss per share from continuing operations adjusted for share-based compensation expense; impairment of long-lived assets, and professional fees associated with MedCath's exploration of strategic options.
Adjusted EBITDA for the 2011 fiscal period represents MedCath's loss from continuing operations, net of taxes, income tax benefit; net income attributable to noncontrolling interests; equity in earnings (losses) of unconsolidated affiliates; interest and other income, net; gain on sale of unconsolidated affiliates; interest expense; (gain) loss on disposal of property, equipment and other assets; impairment of long-lived assets; depreciation; share-based compensation expense, and professional fees associated with MedCath's exploration of strategic options. Adjusted EPS for the 2011 fiscal period represents MedCath's diluted loss per share from continuing operations adjusted for gain on sale of unconsolidated affiliates; professional fees for strategic options process; impairment of long-lived assets, and share based compensation expense.
Adjusted EBITDA for the year ended September 30, 2010 represents MedCath's loss from continuing operations, net of taxes, income tax benefit; net income attributable to noncontrolling interests; equity in earnings (losses) of unconsolidated affiliates; interest and other income, net; loss on note receivable; interest expense; (gain) loss on disposal of property, equipment and other assets; impairment on long-lived assets; depreciation; pre-opening expenses; share-based compensation expense, and professional fees associated with MedCath's exploration of strategic options. Adjusted EPS for the year ended September 30, 2010 represents MedCath's diluted loss per share from continuing operations adjusted for professional fees associated with MedCath's exploration of strategic options; impairment on long-lived assets; loss on note receivable; share-based compensation expense, and pre-opening expense.
MedCath's management uses Adjusted EBITDA to measure the performance of MedCath's various operating entities, to compare actual results to historical and budgeted results and to make capital allocation decisions. Management provides Adjusted EBITDA and Adjusted EPS to investors to assist them in performing their analyses of MedCath's historical operating results. Further, management believes that many investors in MedCath also invest in, or have knowledge of, other healthcare companies that use Adjusted EBITDA and/or Adjusted EPS as a financial performance measure. Because Adjusted EBITDA and Adjusted EPS are non-GAAP measures, Adjusted EBITDA and Adjusted EPS, as defined above, may not be comparable to other similarly titled measures of other companies. MedCath has included a supplemental schedule with the financial statements that accompanies this press release that reconciles historical Adjusted EBITDA to MedCath's income from continuing operations attributable to MedCath's common stockholders and Adjusted EPS to diluted EPS from continuing operations.
This press release and the financial information included therewith will be accessible on the web, by going to www.medcath.com, "Investor Relations," then clicking on "News."
MedCath Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused on high acuity services with the diagnosis and treatment of cardiovascular disease being a primary service offering. MedCath owns an interest in and operates one hospital with a total of 47 licensed beds located in California.
Parts of this announcement contain forward-looking statements that involve risks and uncertainties, including statements regarding the amount of net proceeds to be received from the sale of our interests in Harlingen Medical Center and HMC Realty, LLC. Although management believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic, regulatory and competitive uncertainties and contingencies that are difficult or impossible to predict accurately and are beyond our control. Actual results could differ materially from those projected in these forward-looking statements. We do not assume any obligation to update these statements in a news release or otherwise should material facts or circumstances change in ways that would affect their accuracy. The preparation of MedCath's fourth quarter of fiscal 2011 operating results required management to make estimates and assumptions that affect reported amounts of revenues and expenses. There is a reasonable possibility that actual results may vary significantly from those estimates.
These various risks and uncertainties are described in detail in "Risk Factors" in MedCath's Annual Report or Form 10-K for the year ended September 30, 2011 that was filed with the Securities and Exchange Commission on December 14, 2011. Copies of our filings with the Securities and Exchange Commission, including exhibits, are available at www.sec.gov to review.
MEDCATH CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Going Concern Basis)
(unaudited)
Period July 1, 2011 to September 22, 2011 Three Months Ended September 30, 2010 2011 Fiscal Period Year Ended September 30, 2010
----------------------------------------- ------------------------------------- ------------------ -----------------------------
Net revenue $42,482 $41,414 $167,301 $166,411
Operating expenses:
Personnel
expense 19,231 16,727 72,477 66,734
Medical
supplies
expense 7,468 8,201 32,342 33,410
Bad debt
expense 8,252 5,761 25,908 23,805
Other
operating
expenses 21,175 14,518 65,254 53,459
Pre-opening
expenses - - - 866
Depreciation 1,798 2,586 8,014 12,221
Impairment of
long-lived
assets - 28,509 20,358 66,022
Loss (gain) on
disposal of
property,
equipment and
other assets 79 (33) (226) (54)
Total operating expenses 58,003 76,269 224,127 256,463
------ ------ ------- -------
Loss from
operations (15,521) (34,855) (56,826) (90,052)
Other income
(expenses):
Interest
expense (13) (1,103) (2,320) (3,935)
Interest and
other income 44 10 179 86
Gain on sale
of
unconsolidated
affiliates - - 15,391 -
Loss on note
receivable - - - (1,507)
Equity in net
(losses)
earnings of
unconsolidated
affiliates (462) 1,375 1,216 5,359
---- ----- ----- -----
Total other (expense)
income, net (431) 282 14,466 3
---- --- ------ ---
Loss from
continuing
operations before
income taxes (15,952) (34,573) (42,360) (90,049)
Income tax benefit (5,833) (12,387) (16,963) (33,377)
------ ------- ------- -------
Loss from
continuing
operations (10,119) (22,186) (25,397) (56,672)
Income from
discontinued
operations, net of
taxes 87,283 7,167 154,742 20,690
------ ----- ------- ------
Net income (loss) 77,164 (15,019) 129,345 (35,982)
Less: Net income
attributable to
noncontrolling
interests (46,403) (6,671) (62,709) (12,389)
------- ------ ------- -------
Net income (loss)
attributable to
MedCath
Corporation $30,761 $(21,690) $66,636 $(48,371)
======= ======== ======= ========
Amounts attributable to MedCath Corporation
common stockholders:
Loss from
continuing
operations,
net of taxes $(11,518) $(26,417) $(29,177) $(61,843)
Income from
discontinued
operations,
net of taxes 42,279 4,727 95,813 13,472
Net income
(loss) $30,761 $(21,690) $66,636 $(48,371)
======= ======== ======= ========
Earnings (loss) per
share, basic
Loss from
continuing
operations
attributable to
MedCath
Corporation
common
stockholders $(0.57) $(1.33) $(1.45) $(3.12)
Income from
discontinued
operations
attributable to
MedCath
Corporation
common
stockholders 2.09 0.24 4.75 0.68
---- ---- ---- ----
Earnings
(loss) per
share, basic $1.52 $(1.09) $3.30 $(2.44)
----- ------ ----- ------
Earnings (loss) per
share, diluted
Loss from
continuing
operations
attributable to
MedCath
Corporation
common
stockholders $(0.57) $(1.33) $(1.45) $(3.12)
Income from
discontinued
operations
attributable to
MedCath
Corporation
common
stockholders 2.09 0.24 4.75 0.68
---- ---- ---- ----
Earnings
(loss) per
share,
diluted $1.52 $(1.09) $3.30 $(2.44)
----- ------ ----- ------
Weighted average
number of shares,
basic 20,216 19,898 20,153 19,842
Dilutive effect of
stock options and
restricted stock 6 - 6 -
--- --- --- ---
Weighted average
number of shares,
diluted 20,222 19,898 20,159 19,842
====== ====== ====== ======
MEDCATH CORPORATION
SELECTED OPERATING DATA
(In thousands, except per share data and selected operating data)
(Unaudited)
Period July 1, 2011 to Three Months Ended Year Ended
September 22, 2011 September 30, 2010 % Change 2011 Fiscal Period September 30, 2010 % Change
------------------ ------------------ -------- ------------------ ------------------ --------
Statement of Operations Data:
Net revenue $42,482 $41,414 2.6% $167,301 $166,411 0.5%
Adjusted EBITDA (1) $(6,263) $(457) (1270.5)% $(13,156) $(9,813) (34.1)%
Loss from operations $(15,521) $(34,855) 55.5% $(56,826) $(90,052) 36.9%
Loss from continuing operations, net of taxes $(11,518) $(26,417) 56.4% $(29,177) $(61,843) 52.8%
Loss per share from continuing operations, basic $(0.57) $(1.33) 57.1% $(1.45) $(3.12) 53.5%
Loss per share from continuing operations, diluted $(0.57) $(1.33) 57.1% $(1.45) $(3.12) 53.6%
(1) See Supplemental Financial Disclosure-Reconciliation of GAAP Financial Measures to Non-GAAP Financial
Measures.
Period July 1, 2011 to Three Months Ended Year Ended
September 22, 2011 September 30, 2010 % Change 2011 Fiscal Period September 30, 2010 % Change
------------------ ------------------ -------- ------------------ ------------------ --------
Selected Operating Data (a):
Number of hospitals 3 3 3 3
Licensed beds ( c ) 254 254 254 254
Staffed and available beds ( d ) 214 214 214 214
Admissions ( e ) 1,785 1,989 (10.3)% 7,907 8,380 (5.6)%
Adjusted admissions ( f ) 2,930 3,263 (10.2)% 12,675 13,036 (2.8)%
Patient days ( g ) 7,191 7,755 (7.3)% 31,713 33,041 (4.0)%
Adjusted patient days ( h ) 11,843 12,698 (6.7)% 50,803 51,341 (1.0)%
Average length of stay (days) ( i ) 4.03 3.90 3.3% 4.01 3.94 1.8%
Occupancy ( j ) 36.5% 39.4% 40.6% 42.3%
Inpatient catheterization procedures ( k ) 448 544 (17.6)% 1,778 2,304 (22.8)%
Inpatient surgical procedures ( l ) 399 470 (15.1)% 1,832 2,023 (9.4)%
Combined Operating Data (b):
Number of hospitals 4 4 4 4
Licensed beds ( c ) 366 366 366 366
Staffed and available beds ( d ) 323 323 323 323
Admissions ( e ) 3,396 3,812 (10.9)% 14,662 15,642 (6.3)%
Adjusted admissions ( f ) 6,113 6,529 (6.4)% 25,491 26,398 (3.4)%
Patient days ( g ) 11,908 13,303 (10.5)% 52,450 55,115 (4.8)%
Adjusted patient days ( h ) 21,162 22,638 (6.5)% 90,145 91,957 (2.0)%
Average length of stay (days) ( i ) 3.51 3.49 0.6% 3.58 3.52 1.7%
Occupancy ( j ) 40.1% 44.8% 44.5% 46.7%
Inpatient catheterization procedures ( k ) 690 687 0.4% 2,855 3,048 (6.3)%
Inpatient surgical procedures ( l ) 799 920 (13.2)% 3,469 3,638 (4.6)%
Selected operating data includes consolidated hospitals in operation as of the end of the period reported in
continuing operations but does not include hospitals which are accounted for using the equity method or as
discontinued operations in our consolidated financial statements. The 2011 Fiscal Period is as of September
22, 2011. Subsequent to that date, the Company disposed of its interest in two of the consolidated
(a) hospitals.
Combined operating data includes hospitals in operation as of the end of the period reported in continuing
operations including hospitals which are accounted for using the equity method in our consolidated financial
statements. The 2011 Fiscal Period is as of September 22, 2011. Subsequent to that date, the Company
disposed of its interest in two of the consolidated hospitals and its interest in an equity accounted for
(b) hospital.
(c) Licensed beds represent the number of beds for which the appropriate state agency licenses a facility
regardless of whether the beds are actually available for patient use.
(d) Staffed and available beds represent the number of beds that were readily available for patient use at the
end of the period.
(e) Admissions represent the number of patients admitted for inpatient treatment.
(f) Adjusted admissions is a general measure of combined inpatient and outpatient volume. We computed adjusted
admissions by dividing gross patient revenue by gross inpatient revenue and then multiplying the quotient by
admissions.
(g) Patient days represent the total number of days of care provided to inpatients.
(h) Adjusted patient days is a general measure of combined inpatient and outpatient volume. We computed adjusted
patient days by dividing gross patient revenue by gross inpatient revenue and then multiplying the quotient
by patient days.
(i) Average length of stay (days) represents the average number of days inpatients stay in our hospitals.
(j) We computed occupancy by dividing patient days by the number of days in the period and then dividing the
quotient by the number of staffed and available beds.
(k) Inpatients with a catheterization procedure represent the number of inpatients with a procedure performed in
one of the hospitals' catheterization labs during the period.
(l) Inpatient surgical procedures represent the number of surgical procedures performed on inpatients
during the period.
MEDCATH CORPORATION
SUPPLEMENTAL FINANCIAL DISCLOSURE - RECONCILIATION OF GAAP FINANCIAL MEASURES
TO NON-GAAP FINANCIAL MEASURES
(Unaudited)
The following table reconciles the loss from continuing operations, net of taxes attributable to MedCath Corporation's common stockholders as derived directly from MedCath Corporation's consolidated financial statements to Adjusted EBITDA for the periods indicated.
Period July 1, 2011 to Three Months Ended 2011 Year Ended
September 22, 2011 September 30, 2010 Fiscal Period September 30, 2010
------------------ ------------------ ------------- ------------------
(in thousands) (in thousands)
Loss from continuing operations, net of taxes $(11,518) $(26,417) $(29,177) $(61,843)
Add:
Income tax
benefit (5,833) (12,387) (16,963) (33,377)
Net income
attributable
to
noncontrolling
interests 749 4,231 1,399 (734)
Equity in net
earnings
(losses) of
unconsolidated
affiliates 462 (1,375) (1,216) (5,359)
Interest and
other income (44) (10) (179) (86)
Loss on note
receivable - - - 1,507
Gain on sale of
unconsolidated
affiliates - - (15,391) -
Interest
expense 13 1,103 2,320 3,935
(Gain) loss on
disposal of
property,
equipment and
other assets 79 (33) (226) (54)
Impairment of
long-lived
assets - 28,509 20,358 66,022
Depreciation 1,798 2,586 8,014 12,221
Pre-opening
expenses - - - 866
Share-based
compensation
expense 1,035 772 4,311 3,148
Professional
fees for
strategic
options
process 6,996 2,564 13,594 3,941
Adjusted EBITDA $(6,263) $(457) $(13,156) $(9,813)
======= ===== ======== =======
The following table reconciles MedCath Corporation's diluted (loss) earnings per share from continuing operations, net of taxes attributable to MedCath Corporation's common stockholders as derived directly from MedCath's consolidated financial statements to Adjusted diluted earnings per share
from continuing operations (inclusive of the effect of dilutive shares) for the periods indicated.
Period July 1, 2011 to Three Months Ended 2011 Year Ended
September 22, 2011 September 30, 2010 Fiscal Period September 30, 2010
------------------ ------------------ ------------- ------------------
Diluted (loss) earnings per share $(0.57) $(1.33) $(1.45) $(3.12)
Add:
Gain on sale of
unconsolidated
affiliates - - (0.47) -
Professional
fees for
strategic
options
process 0.21 0.08 0.41 0.12
Impairment of
long-lived
assets - 0.87 0.62 2.02
Loss on note
receivable - - - 0.05
Share-based
compensation
expense 0.03 0.02 0.13 0.10
Pre-opening
expense - - - 0.03
Adjusted diluted loss per share $(0.33) $(0.36) $(0.76) $(0.80)
====== ====== ====== ======
SOURCE MedCath Corporation
